[artículo] 
inThe American Journal of Psychiatry > Año 2021 - Vol. 178 - No.5 (Mayo) . - pp. 437-446

Título :	Impact of the kcnq2/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression : results from a randomized controlled trial
Tipo de documento:	texto impreso
Autores:	Laurel S. Morris, Autor ; Sara Costi, Autor ; Katherine A. Kirkwood, Autor
Fecha de publicación:	2021
Artículo en la página:	pp. 437-446
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Depresión, Antidepresivos, Anhedonia, Neuroimagen, Canal de potasio KCNQ
Resumen:	Preclinical studies point to the KCNQ2/3 potassium channel as a novel target for the treatment of depression and anhedonia, a reduced ability to experience pleasure. The authors conducted the first randomized placebo-controlled trial testing the effect of the KCNQ2/3 positive modulator ezogabine on reward circuit activity and clinical outcomes in patients with depression.
Link:	./index.php?lvl=notice_display&id=26262

[artículo] Impact of the kcnq2/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression : results from a randomized controlled trial [texto impreso] / Laurel S. Morris, Autor ; Sara Costi, Autor ; Katherine A. Kirkwood, Autor . - 2021 . - pp. 437-446.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.5 (Mayo) . - pp. 437-446

Palabras clave:	Depresión, Antidepresivos, Anhedonia, Neuroimagen, Canal de potasio KCNQ
Resumen:	Preclinical studies point to the KCNQ2/3 potassium channel as a novel target for the treatment of depression and anhedonia, a reduced ability to experience pleasure. The authors conducted the first randomized placebo-controlled trial testing the effect of the KCNQ2/3 positive modulator ezogabine on reward circuit activity and clinical outcomes in patients with depression.
Link:	./index.php?lvl=notice_display&id=26262